Evidence map›Paper›PMID 41045333›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout.

Yuchi He, Liangkaobei Chen, Jialong Jia, Yifan Liu, Yuqing Chen, Xiyu Zhang, Ya Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuchi He *Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Liangkaobei Chen *Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jialong JiaChengdu University of Traditional Chinese Medicine, Chengdu, China.
Yifan LiuChengdu University of Traditional Chinese Medicine, Chengdu, China.
Yuqing ChenChengdu University of Traditional Chinese Medicine, Chengdu, China.
Xiyu ZhangDepartment of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Ya LiuDepartment of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. liuyaya918@163.com.

Funding

Science and Technology Department of Sichuan Province 24ZDYF0229
6 · The paper itself

Abstract

Hypertension frequently coexists with gout, and previous studies have suggested a potential association between these conditions. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are essential treatments for hypertension, though their effects on gout risk remains unclear and contradictory. We employed data from the FDA Adverse Event Reporting System (FAERS) alongside two-sample and multivariable Mendelian randomization (MR) analysis to evaluate the independent effects of hypertension, candesartan, lisinopril, and ramipril on gout risk. Analysis of FAERS data revealed that the lower bound of the 95% CI for ROR exceeded 1 for candesartan, lisinopril, and ramipril, suggesting potential associations with gout. However, two-sample MR analysis indicated significant causal links only for ramipril and hypertension. And in multivariable MR analysis, the association remained significant solely for hypertension. In summary, our study identifies a significant causal relationship between hypertension and gout risk but does not support a causal effect for the three antihypertensive medications-candesartan cilexetil, lisinopril, and ramipril.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzimidazolesGoutHypertensionLisinoprilRamiprilTetrazolesBiphenyl CompoundsHumansMendelian Randomization AnalysisAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzimidazolesBiphenyl CompoundscandesartanLisinoprilRamiprilTetrazolesAdverse drug eventsAngiotensin converting enzyme inhibitorsAngiotensin II receptor blockersGoutHypertensionMendelian randomization

Identifiers

PMID41045333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.